Bayer HealthCare LLC, Bayer US Holding LLC, and Priyal Patel filed Amendment No. 2 to a Schedule 13D with the SEC on November 18, 2026, disclosing a combined 6.90% beneficial ownership position in Senti Biosciences Holdings, Inc. (NASDAQ:SNTI), a biosciences company headquartered in South San Francisco, California.
Key Highlights
- Beneficial ownership: Each of the three reporting persons, Bayer HealthCare LLC, Bayer US Holding LLC, and Priyal Patel, is reported to beneficially own 6,142,848 shares, representing 6.90% of Senti Biosciences Holdings common stock.
- Shared voting and dispositive power: All 6,142,848 shares are held with shared voting and shared dispositive power; none are held with sole voting or sole dispositive power by any reporting person.
- Warrant component: The 6,142,848 shares include shares issuable upon full exercise of a warrant held by Bayer HealthCare LLC, with 3,333,000 of those underlying shares exercisable within 60 days of the filing date.
- Share count basis: The 6.90% figure was calculated using 85,706,263 shares of common stock reported as outstanding as of October 30, 2026, per Senti Biosciences' quarterly report for the period ended September 30, 2026.
- Triggering event date: The event requiring this amendment occurred on November 16, 2026, two days before the filing was submitted.
- Source of funds: The filing designates the source of funds as "OO" (other) for all reporting persons.
Bayer Entities and Priyal Patel Detail Their Senti Biosciences Holdings
According to the filing, the three reporting persons - Bayer HealthCare LLC, Bayer US Holding LLC (both organized in Delaware), and Priyal Patel - collectively disclose a 6.90% interest in Senti Biosciences Holdings, Inc., a biosciences company with its principal executive offices at 2 Corporate Drive, First Floor, South San Francisco, California 94080. The filing is Amendment No. 2 to an original Schedule 13D first filed on March 17, 2025, and later amended on April 16, 2026.
The filing notes that the aggregate beneficial ownership figure of 6,142,848 shares includes shares of common stock that would be issuable upon the full exercise of a warrant held by Bayer HealthCare LLC. Of that total, 3,333,000 shares underlying the warrant are described as exercisable within 60 days of the filing date. The percentage calculation is based on 85,706,263 shares of Senti Biosciences common stock reported outstanding as of October 30, 2026, as stated in the issuer's quarterly report filed with the SEC on November 16, 2026. Each reporting person disclaims beneficial ownership of shares other than those each person owns of record, as stated in the filing.
Priyal Patel is identified in the filing as an individual reporting person, with the same 6,142,848 shares and 6.90% figure attributed to her position. Nicholas Massey signed the amendment on November 18, 2026, as attorney-in-fact for Priyal Patel in her capacity as Chief Financial Officer for both Bayer HealthCare LLC and Bayer US Holding LLC. The filing incorporates by reference several previously filed exhibits, including a Joint Filing Agreement, Powers of Attorney, a Certificate of Designation of Series A Convertible Preferred Stock, a Form of Warrant to Purchase Common Stock, and a Securities Purchase Agreement, all originally associated with transactions dated December 2, 2024.
What Was Disclosed
Bayer HealthCare LLC, Bayer US Holding LLC, and Priyal Patel filed Amendment No. 2 to a Schedule 13D reporting 6,142,848 shares, or 6.90%, of Senti Biosciences Holdings common stock, including shares underlying a warrant held by Bayer HealthCare LLC, with the triggering event dated November 16, 2026.



Please wait processing your request...